Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer

被引:58
作者
Potter, SR
Horniger, W
Tinzl, M
Bartsch, G
Partin, AW
机构
[1] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[3] Univ Innsbruck, Dept Urol, Prostate Ctr, A-6020 Innsbruck, Austria
关键词
D O I
10.1016/S0090-4295(01)00980-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives, The decision to perform prostate biopsy has traditionally been based on an abnormal prostate-specific antigen (PSA) level or abnormal digital rectal examination (DRE) findings. For example, a 60-year-old man with a benign DRE and PSA level of 4.1 ng/mL would be counseled for biopsy, and the same man with a PSA level of 3.9 ng/mL might be counseled against biopsy. However, the difference in these PSA levels and in the likelihood of these two men having prostate cancer is not significant. We constructed a probability nomogram for the likelihood of detecting prostate cancer, thus aiding in the decision of whether to perform a prostate biopsy. Methods. Using multivariate logistic regression analysis and data from 2054 men (mean age 64 years) participating in the Tyrol Screening Project between January 9, 1993 and January 9, 1997, patient age, PSA level, and DRE findings were analyzed for their ability to determine the likelihood of finding prostate cancer on transrectal ultrasound-guided biopsy. Results. DRE was suspicious in 278 men (13.5%). Overall, 498 (24.5%) of 2054 men biopsied had prostate cancer. The probability of discovering cancer on biopsy was calculated using patient age, DRE findings, and PSA level. Conclusions. DRE status had a large influence on the likelihood of positive biopsy across all PSA and age ranges. A combination of PSA, DRE result, and age better defined the probability of a positive biopsy than any factor alone. Using this nomogram, the decision to proceed with or defer prostate biopsy can be based on an actual probability of discovering prostate cancer rather than a single PSA-based cutpoint, These data may aid physicians and patients in decision-making. UROLOGY 57: 1100-1104, 2001. (C) 2001, Elsevier Science Inc.
引用
收藏
页码:1100 / 1104
页数:5
相关论文
共 20 条
[1]   Prostate-specific antigen as a screening test for prostate cancer - The United States experience [J].
Arcangeli, CG ;
Ornstein, DK ;
Keetch, DW ;
Andriole, GL .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :299-+
[2]   THE USE OF PROSTATE SPECIFIC ANTIGEN DENSITY TO ENHANCE THE PREDICTIVE VALUE OF INTERMEDIATE LEVELS OF SERUM PROSTATE SPECIFIC ANTIGEN [J].
BENSON, MC ;
WHANG, IS ;
OLSSON, CA ;
MCMAHON, DJ ;
COONER, WH .
JOURNAL OF UROLOGY, 1992, 147 (03) :817-821
[3]   Prostate-specific antigen: Current status [J].
Brawer, MK .
CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (05) :264-281
[4]   An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases [J].
Carlson, GB ;
Calvanese, CB ;
Partin, AW .
UROLOGY, 1998, 52 (03) :455-461
[5]   LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].
CARTER, HB ;
PEARSON, JD ;
METTER, J ;
BRANT, LJ ;
CHAN, DW ;
ANDRES, R ;
FOZARD, JL ;
WALSH, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220
[6]   MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
DODDS, KM ;
COPLEN, DE ;
YUAN, JJJ ;
PETROS, JA ;
ANDRIOLE, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161
[7]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[8]   Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements [J].
Catalona, WJ ;
Smith, DS ;
Ornstein, DK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1452-1455
[9]   COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE-SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE-CANCER - RESULTS OF A MULTICENTER CLINICAL-TRIAL OF 6,630 MEN [J].
CATALONA, WJ ;
RICHIE, JP ;
AHMANN, FR ;
HUDSON, MA ;
SCARDINO, PT ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 151 (05) :1283-1290
[10]   PROSTATE-CANCER DETECTION IN A CLINICAL UROLOGICAL PRACTICE BY ULTRASONOGRAPHY, DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN [J].
COONER, WH ;
MOSLEY, BR ;
RUTHERFORD, CL ;
BEARD, JH ;
POND, HS ;
TERRY, WJ ;
IGEL, TC ;
KIDD, DD .
JOURNAL OF UROLOGY, 1990, 143 (06) :1146-1154